UPDATE: Citigroup Initiates Coverage On DBV Technologies As Stock Is Not Fully Appreciated

In a report published Monday, Citigroup analyst Liav Abraham initiated coverage on DBV Technologies DBVT with a Buy rating and $48.00 price target. In the report, Citigroup noted, “The market is not fully appreciating the value of DBV's technology for the treatment of severe allergies, in our view, with the current share price implying a c.30% probability of success for Viaskin Peanut, vs. our base case assumptions of a 60% and 40% clinical success rates for children and adults, respectively. Our conviction is reinforced by the recent headline data from the Phase IIb VIPES study, which validate DBV's technology, in our view, and imply optionality for its use in the treatment of a variety of food allergies/ indications.” DBV Technologies closed on Friday at $24.16.